• Publications
  • Influence
Apixaban versus warfarin in patients with atrial fibrillation.
TLDR
In patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality. Expand
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice
TLDR
WRITING COMMITTEE MEMBERS* Patrick T. O’Gara, MD, FACC, FAHA, Chair†; Frederick G. Kushner,MD, F ACC,FAHA, FSCAI, Vice Chair*†; Deborah D. Kushner-Kushner, PhD, MBA, FACP, FAha‡; Mina K. Linderbaum, MS, CNP-BC. Expand
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial
TLDR
Cedesartan has a moderate impact in preventing admissions for CHF among patients who have heart failure and LVEF higher than 40%. Expand
Predictors of hospital mortality in the global registry of acute coronary events.
TLDR
Across the entire spectrum of ACS and in general clinical practice, this model provides excellent ability to assess the risk for death and can be used as a simple nomogram to estimate risk in individual patients. Expand
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice
TLDR
The 2017-18 FAHA/FACC/FAHA Education and Research Grants will be focused on advancing the profession’s understanding of central nervous system disorders and the management of post-traumatic stress disorder. Expand
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial
TLDR
The addition of candesartan to ACE inhibitor and other treatment leads to a further clinically important reduction in relevant cardiovascular events in patients with CHF and reduced left-ventricular ejection fraction. Expand
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial
TLDR
Cedesartan was generally well tolerated and reduced cardiovascular mortality and morbidity in patients with symptomatic chronic heart failure and intolerance to ACE inhibitors. Expand
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme
TLDR
Codesartan was generally well tolerated and significantly reduced cardiovascular deaths and hospital admissions for heart failure and there was no significant heterogeneity for candesartan results across the component trials. Expand
A common variant on chromosome 9p21 affects the risk of myocardial infarction.
TLDR
An association between myocardial infarction and a common sequence variant on chromosome 9p21 was associated with the disease with high significance and approximately 21% of individuals in the population are homozygous for this variant, and their estimated risk of suffering myocardious disease is 1.64 times as great as that of noncarriers. Expand
Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank.
TLDR
Red cell distribution width was found to be a very strong independent predictor of morbidity and mortality in 2 large contemporary heart failure populations and may provide novel insights into heart failure pathophysiology. Expand
...
1
2
3
4
5
...